BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its earnings results on Monday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.
BriaCell Therapeutics Stock Down 7.9 %
Shares of BCTX traded down $0.05 on Monday, reaching $0.61. The stock had a trading volume of 2,315,225 shares, compared to its average volume of 1,645,847. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97. The firm has a market capitalization of $22.00 million, a PE ratio of -0.52 and a beta of 1.46. The firm has a 50-day moving average of $0.84 and a 200 day moving average of $0.88.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- Where Do I Find 52-Week Highs and Lows?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
